In over 50% of cases of serous cystadenocarcinoma, SOX2 was expressed in > 75% of the cells of the tissue examined, whereas in only 5% of cases of less severe serous cystadenoma was SOX2 expressed in > 75% of the cells. This evidence concerns the gene SOX2 and serous cystadenocarcinoma.